Dr. Wakelee on Benefits of Osimertinib in EGFR-Mutant NSCLC Treatment
15 Years of Advances in EGFR Mutant Lung CancerПодробнее
Dr. Wakelee on Rationale to Explore Osimertinib With Concurrent Chemotherapy in EGFR-Mutant NSCLCПодробнее
Dr. Wakelee on Recent Advancements in EGFR-Mutant NSCLCПодробнее
Dr. Wakelee on First-Line Therapy for EGFR-Mutant Lung CancerПодробнее
EGFR-Mutant NSCLC: Selecting Patients for OsimertinibПодробнее
Treating Patients With EGFR-Mutant Lung Cancer With Targeted TherapiesПодробнее
Dr. Wakelee on Detection of EGFR T790M Mutation in NSCLCПодробнее
Dr. Wakelee on Explaining Adjuvant Therapy Benefits to PatientsПодробнее
Dr. Wakelee Discusses EGFR TKIs in Lung CancerПодробнее
Repeat biopsy in lung cancer patients with EGFR mutationПодробнее
Dr. Wakelee Discusses Dacomitinib in EGFR+ NSCLCПодробнее
Dr. Kris on Predicting Benefit With Osimertinib in EGFR+ NSCLCПодробнее
Case Based Panel Discussion - EGFR Mutation and Tagrisso - Progression & the Role of Repeat BiopsyПодробнее
Dr. Herbst on the Benefit of Adjuvant Osimertinib in EGFR-Mutant NSCLCПодробнее
Dr. Wakelee Discusses Current State of Treatment in NSCLCПодробнее
Osimertinib in Advanced EGFR T790M-Mutant NSCLCПодробнее
Dr. Wakelee on Available Treatments Following Tumor Progression in Lung CancerПодробнее
Osimertinib’s Value in EGFR-Mutant NSCLCПодробнее
Osimertinib plus gefitinib for treatment of EGFR-mutated non-small cell lung cancerПодробнее
